LINICAL SPAIN SLU

Their core work

Linical Spain SLU is the Spanish branch of a Contract Research Organization (CRO) that provides operational and regulatory services for clinical trials. Their role in H2020 was not as a research institution but as a service provider — likely supplying clinical site management, patient recruitment, regulatory affairs support, or data management to consortia running multi-country trials. Both projects they joined are Phase II–III-level clinical investigations: a rheumatology study on glucocorticoid strategies (GLORIA) and an oncology vaccine trial for acute myeloid leukaemia (AML-VACCiN). As a private company based in Majadahonda — the pharmaceutical hub of Madrid — they are positioned to operate across Spanish clinical sites within large European trial networks.

What they specialise in

How they've shifted over time

With only two projects, both initiated within a 12-month window (2015–2016), there is no meaningful temporal evolution to document. Both engagements sit firmly in clinical trial execution across different therapeutic areas — rheumatology and oncology — suggesting the organisation offers broad-spectrum CRO services rather than deep specialisation in a single disease area. No keyword data is available to detect any shift in focus between these two projects.

Too few data points to identify a direction; their involvement in both immunology and oncology trials suggests they serve as a generalist CRO across therapeutic areas rather than moving toward any single niche.

How they like to work

Linical Spain participated exclusively as a third party in both projects, meaning they were engaged as a contracted service provider rather than as a named consortium member taking intellectual or scientific ownership. Their network of 31 unique partners across 13 countries reflects the scale of the clinical trial consortia they supported, not partnerships they built directly. This pattern is typical of CROs: they are brought in for execution capacity, not for co-design of research.

Through their third-party involvement in two large clinical trial consortia, Linical Spain touched 31 unique partner organisations spanning 13 countries. This reach is a function of the trials' multi-site European design rather than an independently built research network.

What sets them apart

Linical Spain operates from Majadahonda, Madrid — Spain's primary pharmaceutical cluster — which positions them to access a dense concentration of biotech and pharma industry clients and clinical sites. As the Spanish arm of an international CRO, they bring both local regulatory and site knowledge and the process infrastructure of a larger group. For consortia needing Spanish patient cohorts or regulatory submission support in Spain, they offer a ready operational foothold without the overhead of building site capacity from scratch.

Highlights from their portfolio

• AML-VACCiN
  A clinical development programme for a dendritic-cell immunotherapy targeting acute myeloid leukaemia — a high-unmet-need oncology indication — making this one of the more scientifically ambitious trials in the portfolio.
• GLORIA
  A long-running (2015–2021) comparative effectiveness trial in rheumatology that tested a real-world clinical question about glucocorticoid dosing strategies, reflecting Linical Spain's capacity to support multi-year, multi-site trials.